Clinical trials: psoriasis
Plaque Psoriasis
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
- Trial name
- NCT07449702
- Testing
- ORKA-001
- Where
- 39 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Oruka Therapeutics, Inc.
Psoriasis
Enstilar in Combination With Biologic Agents
Patients receiving biologic therapy with 5% or less body surface area will receive Enstilar topical foam for 16 weeks.
- Trial name
- NCT03080545
- Testing
- Enstilar 0.005%-0.064% Topical Foam
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Generalized Pustular Psoriasis
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous study with spesolimab (1368-0013 or 1368-0027).
- Trial name
- NCT03886246
- Testing
- Spesolimab
- Where
- 58 sites in United States, Argentina and 19 more
- Volunteers
- 131 people
- Sponsor
- LEO Pharma
Spondyloarthritis
A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement
Spondyloarthritis refers to a set of inflammatory disorders that mainly afflict the spine, joints and ligaments. A subtype of spondyloarthritis is Ankylosing Spondylitis - now known as axial spondyloarthropathy - which is…
- Trial name
- NCT01969188
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Psoriasis, Rheumatoid Arthritis
BE Study in Patients - Methotrexate Tablets
To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured…
- Trial name
- NCT02940561
- Testing
- Methotrexate - Amneal, Methotrexate - DAVA
- Where
- 3 sites in India
- Volunteers
- 48 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Psoriasis
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream
The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess satisfaction with the treatment.
- Trial name
- psowyn (NCT06180473)
- Testing
- questionnaire
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Psoriasis
Cross Sectional Analysis of Healthcare for Psoriasis in 4 European Countries
Analysis of barriers in psoriasis care from the patient's and the physician's perspective and generation of scientific data on the quality of health care in Denmark, Poland, Spain, and Germany
- Trial name
- PsoBarrier (NCT02668341)
- Testing
- non-interventional
- Where
- 4 sites in Denmark, Germany and 2 more
- Volunteers
- 1,304 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Psoriasis Vulgaris, Psoriatic Arthritis
Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels
In this study, the prevalence of metabolic syndrome in psoriatic and psoriatic arthritis patients as well as the parameters of metabolic syndrome will be examined.
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Metabolic Syndrome
- Trial name
- NCT03932110
- Testing
- omentin, visfatin
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Istanbul Medeniyet University
Arthritis, Psoriatic
Mechanism of Action of Ustekinumab in Psoriatic Arthritis
The purpose of this study is to determine the mechanism of action on target tissue level of ustekinumab treatment in psoriatic arthritis patients.
- Trial name
- MoA anti-p40 (NCT03565042)
- Testing
- Arthroscopy
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Psoriasis
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
The purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis
- Trial name
- AN2728PSR203 (NCT01029405)
- Testing
- AN2728
- Where
- 5 sites in Mexico
- Volunteers
- 145 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
- Trial name
- NCT04541329
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Generalized Pustular Psoriasis
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
This study is a multicenter, single-group, open-label study to evaluate the safety and tolerability of TQH2929 injection at a dose of 900mg in adult subjects with active Generalized Pustular Psoriasis (GPP), and to preliminarily…
- Trial name
- NCT06433531
- Testing
- TQH2929 Injection
- Where
- 7 sites in China
- Volunteers
- 9 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Psoriasis, Periodontal Diseases
Interleukin- 17 (IL-17), Bcl-3, and NF-kappa-B Inhibitor Zeta (IκBζ) Expression Levels in the Psoriasis Patients
This study aimed to compare the levels of IL-17 (interleukin- 17), Bcl-3 (B-cell lymphoma 3-encoded protein), and IκBζ (NF-kappa-B inhibitor zeta) in the gingival crevicular fluid of psoriatic and healthy individuals and the…
- Trial name
- NCT06408454
- Testing
- Gingival crevicular fluid collection, periodontal test
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kahramanmaras Sutcu Imam University
Psoriasis, Plaque-type
Thalidomide in the Treatment of Chronic Plaque Psoriasis.
The objective of this study is to obtain information on the effectiveness of thalidomide in psoriasis.
- Trial name
- NCT01891019
- Testing
- Thalidomide oral
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University
Carpal Tunnel Syndrome, Psoriatic Arthritis
Carpal Tunnel Syndrome in Patients With Psoriatic Arthritis; Ultrasonography and Magnetic Resonance Imaging Findings
This study aimed to investigate relationship between CTS diagnosis with electrodiagnostic studies and median nerve's cross-sectional area measered by US and MRI in PsA patients.
- Trial name
- NCT05086042
- Testing
- Ultrasonography, Magnetic resonance imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Selcuk University
Psoriasis
A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting.
- Trial name
- G-START (NCT07746583)
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Janssen-Cilag Kft.
Rheumatoid Arthritis, Ankylosing Spondylitis
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- CannabisRIC (NCT04402554)
- Testing
- Cannabis questionnaire
- Where
- France
- Volunteers
- 501 people
- Sponsor
- University Hospital, Clermont-Ferrand
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic…
- Trial name
- reSURFACE 1 (NCT01722331)
- Testing
- Tildrakizumab 200 mg, Tildrakizumab 100 mg
- Volunteers
- 772 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group.
- Trial name
- NCT07724366
- Testing
- TQH3906 capsules, Deucravacitinib tablets 6 mg
- Where
- 45 sites in China
- Volunteers
- 400 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
Community Based Trial for AMEVIVE®
To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
- Trial name
- NCT00168753
- Testing
- Alefacept
- Where
- 36 sites in United States
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.